NF-kappa B pathway inhibitors (NCI/NIH OTT)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNF-kappa B pathway inhibitors (NCI/NIH OTT)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInhibitor of nuclear factor kappa-B kinase subunit beta inhibitorsNuclear factor NF-kappa-B complex inhibitors
TargetsInhibitor of nuclear factor kappa-B kinase subunit betaNuclear factor NF-kappa-B complex
Therapy Area/IndicationsInflammationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsInflammationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A